This has changed the pediatric rheumatology landscape substantially, but improvements in the use of anti-TNF drugs are still needed, especially since anti-TNF drugs will be used earlier in the disease course when following recent international adaptations of JIA treat-to-target strategies [6]. Here, TNF is linked to juvenile idiopathic arthritis.